

# Scientific Program

Saturday 12 October 2019

<b>08:00-08:20 Welcome ceremony</b>			
Room:	Plenary Hall A		
Chair:	Frank May FISPE, ACPE12 Conference Co-Chair		
	Koji Kawakami, ACPE12 Conference Co-Chair and Local Host Committee Chair; Kyoto University, Japan Almut Winterstein FISPE, President, International Society for Pharmacoepidemiology; University of Florida, USA Kiyoshi Kubota FISPE, President, Japanese Society for Pharmacoepidemiology; NPO Drug Safety Research Unit Japan, Japan		
<b>08:30-10:00</b>	<b>Contributed papers 1 - Substance abuse, opioids and pain</b>	<b>Symposium 1 - Variability and generalizability of claims-based algorithms in pharmacoepidemiologic research: Multinational perspectives</b>	<b>Symposium 2 - Data science and Pharmacoepidemiology in the next 10 Years</b>
Room:	Conference Room	Plenary Hall A	Exhibition Hall A
Chair/ Moderator:	Daisuke Koide, The University of Tokyo, Japan Mary-Beth Ritchey FISPE, RTI Health Solutions, USA	Soko Setoguchi FISPE, Rutgers University, USA Chieko Ishiguro, Pharmaceuticals and Medical Devices Agency (PMDA), Japan	Wei Zhou FISPE, Merck Research Laboratories, USA
08:30-08:45	The impact of substance abuse on healthcare resource utilization: Big data analytics using the clinical data in Hong Kong - #100 Yue Wei, The University of Hong Kong, China	The importance of validating outcomes when using claims data Brian Strom FISPE, Rutgers University, USA	Data science and pharmacoepidemiology in RWE: What can we learn from each other and where must we differ Almut G. Winterstein FISPE, University of Florida, USA
08:45-09:00	Understanding patients with substance abuse and their healthcare pathway by using bigdata approach: Towards better management in Hong Kong - #101 Jia Xi Zhao, The University of Hong Kong, China	Operational challenges in the execution of validation studies of claims data in Japan: A review of inter-hospital variability of results from the Japan VALIDATE study Cynthia de Luise, Pfizer, USA	Overview in the use of RWE in the drug approval process and related challenges Nancy Santanello FISPE, Consultant, USA
09:00-09:15	The effects of more restrictive scheduling in 2018 on subsequent codeine use and harms in Australia - #102 Nicholas Buckley, NSW Poisons Information Centre; The University of Sydney, Australia	Validating administrative health data in Australia Benjamin Daniels, University of New South Wales, Australia	A perspective from Asia: RWE experience in Japan Koji Kawakami, Kyoto University, Japan
09:15-09:30	Transition to high-dose or strong opioids: A population-based study of people initiating opioids in Australia - #103 Jenni Ilomäki, Monash University, Australia		
09:30-09:45	A spatial-temporal analysis of adverse drug reactions due to opioid analgesic use in New South Wales - #104 Wei Du, Australian National University, Australia		
09:45-10:00	Trend in targeted therapy in patients with rheumatoid arthritis in Korea: A time-series analysis using nationwide health insurance data, 2010-2017 - #105 So-Hee Park, Sungkyunkwan University, South Korea		
<b>10:00-10:30 Morning coffee break with poster discussions</b>			
Room:	Plenary Hall B		
	Presenters of original research within the following abstract themes will be attending their poster during the morning tea break for discussions with interested delegates. Pharmacoepidemiology and traditional medicines (poster boards 364 – 382) Pharmacogenomics research and drug safety (poster boards 383 – 388) Pharmaceutical policy and administration (poster boards 389 – 391) Other related fields (poster boards 426 – 449) Evidence-based medicine (poster boards 450 – 462) Prevention of medication errors and drug misuse/abuse (poster boards 463 – 466) Rational drug use (poster boards 467 – 474) Evidence-based pharmacy (poster boards 506 – 509) Rare disease and orphan medicines (poster boards 510 – 512) Post-marketing drug effectiveness and safety evaluation (poster boards 513 – 532)		

<b>10:30-12:00</b>	<b>Contributed papers 2 – Patient management and palliative care</b>	<b>Symposium 3 - Challenges and strategies in the post market studies of Herbal and Traditional Medicine (HTM) products</b>	<b>Symposium 4 – Approaches to assess medication exposure and associated risks during pregnancy using Real-World Data</b>
Room:	Conference Room	Plenary Hall A	Exhibition Hall A
Chair/ Moderator:	<b>Keisuke Matsubayashi</b> , Kyoto University, Japan <b>Nicole Pratt</b> , University of South Australia	<b>Soko Setoguchi</b> FISPE, Rutgers University, USA	<b>Kenneth Man</b> , University College London, UK; University of Hong Kong, Hong Kong <b>Keiko Asao</b> , Amgen Astellas BioPharma K.K., Japan
10:30-10:45	<b>Assessment of impact of different instructional interventions in training on inhalers amongst asthma and COPD patients - #106</b> Shilpa Palaksha, JSS College of Pharmacy, India	<b>Real-world evidence initiative in China: An overview and its application to traditional Chinese medicine</b> Xin Sun, West China Hospital, Sichuan University, China	<b>Use of RWD and pregnancy registries in the United States to assess medication exposure and associated risks during pregnancy</b> Jeff Lange, Amgen Inc., USA
10:45-11:00	<b>Impact of clinical pharmacist-led education on clinical and humanistic outcome of children with Thalassemia: A randomized control study - #107</b> Juny Sebastian, JSS College of Pharmacy, India	<b>Safety regulation of herbal medicines of Korea</b> Seong-Gyu Ko, Kyung Hee University College of Korean Medicine, Korea	<b>Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: Population based cohort study</b> Kenneth KC Man, University College London, UK; University of Hong Kong, Hong Kong
11:00-11:15	<b>Reducing medication burden in residential aged care: Simplification of Medications Prescribed to Long-Term care Residents (SIMPLER) cluster randomised controlled trial - #108</b> Jenni Iiomaki and J Simon Bell, Monash University, Australia	<b>Current registration and review of Kampo products in Japan</b> Takeshi Yoshioka, KOKANDO Co. Ltd., Japan	<b>Maternal-infant link using a Japanese administrative dataset</b> Maki Ueyama, Creativ-Ceutical K.K., Japan
11:15-11:30	<b>Efficacy of anti-emetic regimen in chemotherapy induced nausea vomiting and its impact on quality of life in pediatric cancer population - #109</b> Vanitha Rani Nagasubramanian, Sri Ramachandra Institute of Higher Education and Research, India	<b>Pharmacovigilance practice of TCM drugs: Current status, challenges, and future directions</b> Li Zhang, Dongfang Hospital, Beijing University of Chinese Medicine, China	<b>Examination of the prescription of antiepileptic drugs to prenatal and postpartum women in Japan from an administrative dataset</b> Tomofumi Ishikawa, Tohoku University, Japan
11:30-11:45	<b>A Delphi study on the development of a risk proportionality framework for the selection of risk minimisation interventions in Asia - #110</b> Yola Moride FISPE, Université de Montreal, Canada; Rutgers, The State University of New Jersey, USA; YOLARX Consultants, Canada		
11:45-12:00	<b>The association between partner bereavement and incident psoriasis or atopic eczema: A matched cohort study - #111</b> Angel Wong, London School of Hygiene and Tropical Medicine, UK		
<b>12:00-12:30</b>	<b>Lunch (Bento box provided)</b>		
Room:	Plenary Hall A		
<b>12:00-12:15</b>	<b>JSPE General Meeting (日本薬剤疫学会全体総会)</b>		
Room:	Conference Room		
<b>12:30-13:30</b>	<b>Plenary Presentation</b>		
Room:	Plenary Hall A		
Chair/ Moderator:	<b>Siyam Zhan</b> , President, Chinese Society for Pharmacoepidemiology, Peking University, Beijing China <b>Hisashi Urushihara</b> , Keio University, Japan		
	<b>Pharmacoepidemiology methods: Past, present, and advice about the future - #112</b> <b>Brian Strom</b> FISPE, Inaugural Chancellor of Rutgers Biomedical and Health Sciences, and Executive Vice President for Health Affairs at Rutgers University, USA		
<b>13:30-15:00</b>	<b>Contributed papers 3 – Diabetes and other cardiovascular issues</b>	<b>Symposium 5 - Use of real-world evidence (RWE) in regulatory decision-making: Regulatory guidance and examples from Asia and the US</b>	<b>Contributed papers 4 – Paediatrics</b>
Room:	Conference Room	Plenary Hall A	Exhibition Hall A

<b>Chair/ Moderator:</b>	<b>Chieko Ishiguro</b> , Pharmaceuticals and Medical Devices Agency (PMDA), Japan <b>Byung-Joo Park FISPE</b> , Seoul National University College of Medicine, Korea	<b>Darren Toh FISPE</b> , Harvard Medical School and Harvard Pilgrim Health Care Institute, USA	<b>Almut Winterstein FISPE</b> , University of Florida, USA <b>Ju-Young Shin</b> , Sungkyunkwan University, South Korea
13:30-13:45	<b>Antipsychotics use during pregnancy and the risk of gestational diabetes: A population-based cohort study - #113</b> Zixuan Wang, UCL School of Pharmacy, UK	<b>Introduction and overview of the symposium</b> Darren Toh FISPE, Harvard Medical School and Harvard Pilgrim Health Care Institute, USA	<b>Association between relative age within school year and attention deficit hyperactivity disorder (ADHD), intellectual disability and depression - #119</b> Jeremy Brown, London School of Hygiene and Tropical Medicine, UK
13:45-14:00	<b>Continuation of antipsychotic medication during pregnancy and the risk of gestational diabetes: A population-based cohort study - #114</b> Zixuan Wang, UCL School of Pharmacy, UK	<b>Regulatory approach to Real-World Evidence in the United States</b> Jeremy Rassen, Aetion, Inc., USA	<b>Efficacy of pidotimod in children: A systematic review - #120</b> Qiusha Yi, Sichuan University, China
14:00-14:15	<b>Pharmacological treatment dynamics in people initially prescribed metformin or sulfonylurea for type 2 diabetes - #115</b> Stephen Wood, Monash University, Australia	<b>Regulation for Use of Real-World Evidence in post-marketing drug safety assessment in Japan</b> Yusuke Okada, Pharmaceuticals and Medical Devices Agency (PMDA), Japan	<b>Antimicrobial resistant and prescribing pattern in children in Taiwan- TARPEC project - #121</b> Ching-Lan Cheng, National Cheng Kung University Hospital, Taiwan
14:15-14:30	<b>Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors: A pharmacoepidemiological-pharmacodynamic assessment through an analysis of the VigiBase® - #116</b> Faizan Mazhar, Università di Milano, Italy	<b>Use of Real-World Evidence to support drug development and regulatory decision in China</b> Jasmanda Wu, Sanofi, USA and China	<b>Patterns of methylphenidate and atomoxetine use among pediatric patients with attention-deficit/hyperactivity disorder in Taiwan from 2004 to 2017 - #122</b> Heng-Ching Liao, National Taiwan University, Taiwan
14:30-14:45	<b>The use of insulin, diabetes status, and risk of progression after first episode of acute pancreatitis: A population-based cohort study - #117</b> Jaelim Cho, University of Auckland, New Zealand	<b>Regulatory perspective and application of Real-World Evidence in Taiwan</b> Chi-Chuan Wang, National Taiwan University, Taiwan	<b>Association between methylphenidate and risk of seizure: A population-based self-controlled case series study - #123</b> Kenneth Man, University College London, UK; University of Hong Kong, Hong Kong
14:45-15:00	<b>Impact of multiple cardiovascular medication on mortality after an incidence of stroke: A 10-year cohort study - #118</b> Tiantian Ma, UCL School of Pharmacy, UK	<b>Panel Discussion</b> Darren Toh FISPE, Harvard Medical School and Harvard Pilgrim Health Care Institute, USA	<b>Comparative effect of four antimalarial treatments on haematocrit in children in Southwest Nigeria - #124</b> Zacchaeus Olofin, University of Ibadan, Nigeria
<b>15:00-15:45</b>	<b>Afternoon coffee break with poster discussions</b>		
<b>Room:</b>	Plenary Hall B		
	Presenters of original research within the following abstract themes will be attending their poster during the afternoon tea break for discussions with interested delegates. Pharmacoepidemiology and Pharmacovigilance research methods (poster boards 332 – 363) Drug utilization evaluation studies (poster boards 392 – 425) Drug safety risk monitoring, evaluation and prevention (poster boards 475 – 505)		
<b>15:45-17:15</b>	<b>Contributed papers 5 - Cardiovascular and liver issues</b>	<b>Symposium 6 - Japan In Real Life: Data, evidence and an evolving regulatory framework for Pharmacovigilance</b>	<b>Contributed papers 6 - Dementia and older person issues</b>
<b>Room:</b>	Conference Room	Plenary Hall A	Exhibition Hall A
<b>Chair/ Moderator:</b>	<b>Tsugumichi Sato</b> , Tokyo University of Science, Japan <b>Vincent Lo Re</b> , University of Pennsylvania, USA	<b>Robert Reynolds FISPE</b> , GSK R&D, USA	<b>Hisashi Urushihara</b> , Keio University, Japan <b>Takuhiro Yamaguchi</b> , Tohoku University, Japan

15:45-16:00	<b>Comparative risks of cardiovascular events associated with anti-VEGF therapy in real-life patients with macular diseases in Taiwan - #125</b> Wan-Ju Lee, National Cheng Kung University, Taiwan	<b>Introduction: Evolving pharmacovigilance regulations in Japan</b> Robert Reynolds FISPE, GSK R&D, USA	<b>Does statin use change in relation to the initiation of dementia medicine? Analysis of the Australian pharmacy claims data - #131</b> Leonie Picton, Monash University, Australia
16:00-16:15	<b>Acute kidney injury associated with non-steroidal anti-inflammatory drugs and concomitant use of renin-angiotensin system inhibitors and diuretics: A case-crossover study - #126</b> Shao-En Weng, National Taiwan University, Taiwan	<b>Real world data-driven evidence: Experience in outcomes research and safety assessment in Japan</b> Masato Takeuchi, Kyoto University, Japan	<b>Benzodiazepines, Z-hypnotics and risk of dementia: Special considerations of half-lives and concomitant use - #132</b> Shih Tsung Huang, National Taiwan University, Taiwan
16:15-16:30	<b>Prevalence of aspirin non-responsiveness and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention - #127</b> Sheetal Chauhan, Manipal Academy of Higher Education, India	<b>PMDA's experience of MID-NET utilization for postmarketing drug safety assessment</b> Takashi Ando, Pharmaceuticals and Medical Devices Agency(PMDA), Japan	<b>Trazodone use and risk of dementia: A population-based cohort study - #133</b> Wallis C.Y. Lau, University College London, UK
16:30-16:45	<b>Statin-associated dose-dependent reductions in non-alcoholic fatty liver diseases among people without any liver disease - #128</b> Sunyoung Cho, Yonsei University, South Korea	<b>How pharmaceutical companies are using RWD for safety assessment</b> Cynthia de Luise, Pfizer, USA	<b>The association between cholinesterase inhibitors and subsequent cardiovascular events among older patients with Alzheimer's disease in Taiwan - #134</b> Chung-Hsuen Wu, Taipei Medical University, Taiwan
16:45-17:00	<b>Effect of early initiating statin therapy on long-term outcomes of patients with dyslipidemia after intracerebral haemorrhage - #129</b> Ming-Shyan Lin, Chang Gung Memorial Hospital, Taiwan	<b>Applying lessons from the US/EU experience to use RWD and produce valid RWE in Japan</b> Soko Setoguchi FISPE, Rutgers University, USA	<b>Acetylcholinesterase inhibitors, cardiosuppressive drugs, and adverse cardiac events in patients with dementia - #135</b> Izumi Sato, Rutgers University, USA; Kyoto University, Japan
17:00-17:15	<b>Effect of synbiotic, probiotic and prebiotic on patients with non-alcoholic fatty liver disease: A systematic review and network meta-analysis - #130</b> Surasak Saokaew, University of Phayao, Thailand		<b>Androgen deprivation therapy and the risk of dementia in Taiwan - #136</b> Chin Yao Shen, National Cheng Kung University, Taiwan
17:15-18:00	<b>Introduction to Asian Pharmacoepidemiology (AsPEN) Symposium</b>		
Room:	Plenary Hall A		
Co-Chairs	Nicole Pratt, University of South Australia, Australia Kiyoshi Kubota FISPE, NPO Drug Safety Research Unit Japan, Japan		
	<b>Introduction to AsPEN</b> Nam-Kyong Choi, Ewha Womans University, South Korea  <b>Examples of AsPEN collaborative work:</b>  <b>Common Data Model in AsPEN</b> Edward Chia-Cheng Lai, National Cheng Kung University, Taiwan  <b>Example of collaborative projects among AsPEN collaborators</b> Ju-Young Shin, Sungkyunkwan University, South Korea  <b>AsPEN achievements so far and the way forward</b> Kenneth Man, University College London, UK; University of Hong Kong, Hong Kong  <b>Panel discussion</b>		
18:00	End of day 1		
19:00-22:00	<b>Conference dinner</b> The Sodoh Higashiyama Kyoto, 30 - 40 min by bus/taxi from Miyako Messe. Shuttle bus service from Miyako Messe is available for free. Advance application is necessary.		

# Sunday 13 October 2019

08:00-09:30	<b>Contributed papers 7 - Statistical methods and signal detection</b>	<b>Symposium 7 - Real World Evidence to support new drug approval and label expansion</b>	<b>Symposium 8 - Post-market surveillance of medicines, vaccines and medical devices across the Asia-Pacific region: The next 10 Years</b>
Room:	Conference Room	Plenary Hall A	Exhibition Hall A
Chair/ Moderator:	<b>Kotonari Aoki</b> , Chugai Pharmaceuticals, Japan <b>Shiro Tanaka</b> , Kyoto University, Japan	<b>K. Arnold Chan FISPE</b> , National Taiwan University, Taiwan	<b>Edward Chia-Cheng Lai</b> , National Cheng Kung University, Taiwan <b>Nam-Kyong Choi</b> , Ewha Womans University, South Korea <b>Kenneth Man</b> , University College London, UK; University of Hong Kong, Hong Kong
08:00-08:15	<b>Caveats on adjustment for additional confounders following insufficient propensity score balancing - #200</b> Tomohiro Shinozaki, Tokyo University of Science, Japan	<b>Overview</b> K. Arnold Chan FISPE, National Taiwan University, Taiwan	<b>Introduction</b> Edward Chia-Cheng Lai, National Cheng Kung University, Taiwan Kenneth Man, University College London, UK; University of Hong Kong, Hong Kong
08:15-08:30	<b>Multiple imputation for survival analysis with missing covariates using non-parametric estimation - #201</b> Yoshinori Takeuchi, The University of Tokyo, Japan	<b>Use cases of Real World Evidence to support drug applications</b> Jeff Lange, Amgen Inc., USA	<b>AsPEN-Vaccines SIG: Establishing an active vaccine safety monitoring system</b> Nam-Kyong Choi, Ewha Womans University, South Korea
08:30-08:45	<b>A comparison of structural nested accelerated failure-time models and structural nested mean models for survival outcomes - #202</b> Shiro Tanaka, Kyoto University, Japan	<b>Utilization of Real World Data to support new drug approval: PMDA perspective</b> Yuki Ando, Pharmaceuticals and Medical Devices Agency (PMDA), Japan	<b>AsPEN-Biologics SIG: Post-marketing safety evaluation of immune check point inhibitor with the use of historical comparator</b> Ju-Young Shin, Sungkyunkwan University, South Korea
08:45-09:00	<b>Comparison of dynamic treatment regime using inverse probability weighting for dialysis patients - #203</b> Yukari Uemura, National Center for Global Health and Medicine, Japan	<b>How to assess Real World Data quality</b> Wei Zhou FISPE, Merck Research Laboratories, USA	<b>AsPEN-Medical device SIG: Identifying predictors of medical device complications using medication prescribing patterns</b> Nicole Pratt, University of South Australia, Australia
09:00-09:15	<b>Analysis of spontaneous adverse event reports derived from real-world EMR data for prospective pharmacovigilance - #204</b> Hyunah Shin, Konyang University Hospital, South Korea	<b>Methodology consideration for using RWE for new drug application and label expansion</b> K. Arnold Chan FISPE, National Taiwan University, Taiwan	<b>Panel discussion</b> Session moderators, speakers and Gianluca Trifiro, University of Messina, Italy; Mary-Beth Ritchey FISPE, RTI Health Solutions, USA
09:15-09:30	<b>Evaluation of Tree-based Scan Statistic for drug safety signal detection in a Chinese healthcare database: A Plasmode simulation - #205</b> Hailong Li, Sichuan University, China	<b>Discussion</b>	
09:30-11:00	<b>Morning coffee break with poster discussions</b> Presenters of all original research will be attending their poster during the morning tea break for discussions with interested delegates.		
Room:	Plenary Hall B		
09:45-11:00	<b>Spotlight poster presentations (poster boards 300 - 331)</b> A range of notable poster research reports have been pre-selected, and poster presenters will deliver a three minute description of their work followed by moderated audience discussions.		
	<b>Policy, intervention and validation</b>	<b>Real world safety and effectiveness</b>	<b>Pharmacovigilance and drug safety</b>
Room:	Conference Room 2	Conference Room 3	Craft Classroom
Moderator:	<b>Nam-Kyong Choi</b> , Ewha Womans University, South Korea	<b>Mary-Beth Ritchey FISPE</b> , RTI Health Solutions, USA	<b>Nicole Pratt</b> , University of South Australia, Australia
	<b>Insights of healthcare work-force on establishing medication error reporting system in a tertiary care teaching hospital: A survey questionnaire - #300</b> Sri Harsha Chalasani, JSS College of Pharmacy, India	<b>Effect of antipsychotics use on ischemic stroke in patients with atrial fibrillation and dementia - #311</b> Le Dai, National Taiwan University, Taiwan	<b>Existence of notoriety bias in FDA Adverse Event Reporting System (FAERS) Database and its impact on signal strength - #322</b> Subeesh Kulangara Viswam, M.S. Ramaiah University of Applied Science, India
	<b>Current status of re-examination of new drugs on regulatory safety actions in Korea - #301</b> Na-Young Jeong, Ewha Womans University, South Korea	<b>The effectiveness of early use of long-acting injectable antipsychotics in patients with schizophrenia - #312</b> Su-Chen Fang, Taipei City Hospital, Taiwan	<b>Aromatase inhibitors associated with osteonecrosis of Jaw: A disproportionality analysis in the USFDA Adverse Event Reporting System (FAERS) - #323</b> Subeesh Kulangara Viswam, M.S. Ramaiah University of Applied Science, India

	<p>Trends and pattern of antibiotic prescriptions for adult outpatients with acute upper respiratory tract infections in Japan, 2008-2018 - #302 Lyu Ji, Kyoto University, Japan</p>	<p>The effectiveness of febuxostat in moderate to advanced chronic kidney disease patients with hyperuricemia or gout: A population-based study - #313 Chien Huei Huang, National Cheng Kung University Hospital, Taiwan</p>	<p>Population differences in incidence of allopurinol-related severe cutaneous adverse reactions in East Asians - #324 Kimie Sai, National Institute of Health Sciences, Japan</p>
	<p>Prevalence of potential drug-drug interactions in patients undergoing chemoradiotherapy and the impact of an expert team intervention - #303 Ashwin Kamath, Manipal Academy of Higher Education, India</p>	<p>Longitudinal impact of frailty and polypharmacy on risk of mortality in the elderly: A retrospective cohort study - #314 Shih Tsung Huang, National Taiwan University, Taiwan</p>	<p>Anomaly detection as a signal of adverse drug event from claims database: A case example of SGLT2 inhibitors - #325 Masato Takeuchi, Kyoto University, Japan</p>
	<p>Impact of drug safety communication on the use of hydroxyethyl starch in Taiwan: An interrupted time series study - #304 Chih-Wan Lin, National Taiwan University, Taiwan</p>	<p>Real-world effectiveness of switching from statin monotherapy to ezetimibe/simvastatin combination therapy - #315 Tsung Hsuan Lin, Chi Mei Medical Center, Taiwan</p>	<p>Association between diabetes treatment and urinary tract infections: An analysis using data from the JMDC claims database - #326 Akiko Tamon, Intage Healthcare Inc., Japan</p>
	<p>Association between pharmaceutical industry payments and prescribing a fixed-dose combination memantine extended released and donepezil: A cross-sectional study - #305 Zachary Marcum, University of Washington, USA</p>	<p>Effectiveness of statins for primary prevention of cardiovascular disease in an elderly Asian population - #316 Yu-Wen Lin, National Taiwan University, Taiwan</p>	<p>Proton-pump inhibitor use and the risk of progression to end-stage renal disease among chronic kidney disease patients in Taiwan - #327 Chih-Jung Tsai, and Chien Huei Huang, National Cheng - Kung University, Taiwan</p>
	<p>Validity assessment of self-reported medication use in a pharmacoepidemiology research (by comparing to medical and pharmacy insurance claims) - #306 Minako Matsumoto, Keio University School of Medicine, Japan</p>		<p>Undela sheet: One platform for all quantitative signal detection analyses in Pharmacovigilance - #328 Krishna Undela, JSS College of Pharmacy, JSS Academy of Higher Education &amp; Research, India</p>
	<p>Impact of pharmacist care in medication dosing practices of paediatric dosage forms among caregivers - #307 Vasista Sharma, M.S Ramaiah University of Applied Sciences, India</p>	<p>Enoxaparin versus aspirin and aspirin combination in patients with spontaneous intracerebral haemorrhage - #318 Sreedharan Nair, Manipal College of Pharmaceutical Sciences, India</p>	<p>Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: A retrospective cohort study - #329 Wen Wang, West China Hospital, Sichuan University, China</p>
	<p>Validating the diagnosis of acute stroke in Japanese DPC data from Shiga Stroke and Heart Attack Registry - #308 Sachiko Tanaka, Shiga University of Medical Science, Japan</p>	<p>Duloxetine use and risk of coronary artery disease: Systematic review and meta-analysis - #319 Kyoungsoon Park, Seoul National University, South Korea</p>	<p>Safety analysis of pneumococcal vaccine in Korea using the KAERS database from 2005 to 2017 - #330 SeoungHun You, Chung-Ang University, South Korea</p>
	<p>Regimen and adverse drug reactions of anti-tuberculosis treatment and its associated direct medical costs – a patient cohort-based analysis - #309 Biao Xu, Fudan University, China</p>	<p>Combination of glycopeptide and <math>\beta</math>-lactam and risk of acute kidney injury - #320 Chi-Hao Shao, National Taiwan University, Taiwan</p>	<p>Predictors and preventability of adverse events following anaesthesia: An active surveillance in a tertiary care hospital - #331 Sri Harsha Chalasani, JSS College of Pharmacy, India</p>
	<p>Validation of renal failure diagnosis using laboratory data in the MDV database - #310 Naoyuki Yamamoto, CAC Croit Corporation, Japan</p>	<p>Associations among antipsychotics, metabolism-related diseases, and cataracts in patients with schizophrenia: A retrospective cohort study - #321 Yu-Hsuan Shao, Taipei Medical University, Taiwan</p>	
11:00-12:30	<b>Contributed papers 8 – Adherence and prescription trends</b>	<b>Symposium 9 - Real World Evidence for decision making: Where we are in the Asia Pacific region?</b>	<b>Contributed papers 9 – Validation studies</b>
Room:	Conference Room	Plenary Hall A	Exhibition Hall A
Chair/ Moderator:	Takeo Nakayama, Kyoto University, Japan Edward Lai, National Cheng Kung University, Taiwan	Kiyoshi Kubota FISPE, NPO Drug Safety Research Unit Japan, Japan	Yoshinori Takeuchi, The University of Tokyo, Japan Nam-Kyong Choi, Ewha Womans University, South Korea

11:00-11:15	<b>Medication non-adherence and its predictors among new antihypertensive initiators in Japanese working age patients - #206</b> Shiori Nishimura, The University of Tokyo; Keio University School of Medicine, Japan	<b>Development and use of healthcare databases for safety and effectiveness assessment</b> Solomon Iyasu, MSD, USA	<b>Development and validation of ICD-10-based disease scoring system - #212</b> Young-Jin Ko, Seoul National University College of Medicine, South Korea
11:15-11:30	<b>Adherence, persistence and clinical outcome between generic and brand-name statin users: Retrospective cohort study using Japanese claims database - #207</b> Jingwei Gao, Kyoto University, Japan	<b>RWE generation using healthcare databases by study design in Korea</b> Byung-Joo Park FISPE, Seoul National University College of Medicine, Korea	<b>Development and validation of multi-view inappropriate medication use prescription detection model - #213</b> Zhuo Lin, Peking University, China
11:30-11:45	<b>Participation in randomized controlled trials and subsequent medication adherence and quality of treatment in patients with cardiovascular diseases - #208</b> Natalia Vasyukova, National Medical Research Center for Preventive Medicine, Russian Federation	<b>RWE generation from Industry perspective: How this can inform clinical practice and why Industry needs to collaborate</b> Daniel J. Ruzicka, MSD KK, Japan	<b>Impact of chronological changes in propensity to be exposed a comparison validity in health insurance claim database - #214</b> Daisuke Kato, Keio University; Astellas Pharma Inc., Japan
11:45-12:00	<b>Trends and evaluation of online prescription fill among adults in the United States, 2009-2017 - #209</b> Lin-Ya Yang, Taipei Medical University, Taiwan	<b>PMDA's initiative on real world data utilization for regulatory purposes</b> Yoshiaki Uyama, Pharmaceuticals & Medical Devices Agency, Japan	<b>Validity of claims-based definitions for ulcerative colitis in Japan: Methodology and pilot study results from the Validate-JUC study - #215</b> Sean Gardiner, Pfizer Japan Inc, Japan
12:00-12:15	<b>Adverse drug reactions of Yunnan Baiyao capsule: A multi-center intensive monitoring study in China - #210</b> Bo Li, Beijing Hospital of Traditional Chinese Medicine, Beijing, China		<b>Validity of claims-based definitions for rheumatoid arthritis, selected cancers and infectious diseases in Japan: Results from validate-J study - #216</b> Naonobu Sugiyama, Pfizer, Japan
12:15-12:30	<b>An interrupted time series analysis for use of psychoactive medicines in Japan - #211</b> Tasuku Okui, Kyusyu University Hospital, Japan		<b>Identifying incident cancer cases in medicine dispensing claims: A validation study using Australia's Pharmaceutical Benefits Scheme (PBS) data - #217</b> Benjamin Daniels, University of New South Wales, Australia
<b>12:30-14:00</b>	<b>Lunch (Bento box provided)</b>		
<b>Room:</b>	Plenary Hall A		
<b>14:00-15:30</b>	<b>Contributed papers 10 - Bone and biologics</b>	<b>Symposium 10 - Lessons learned and future challenges in international signal detection</b>	<b>Symposium 11 - Modern teaching of Pharmacoepidemiology in a 'Big Data' World</b>
<b>Room:</b>	Conference Room	Plenary Hall A	Exhibition Hall A
<b>Chair/ Moderator:</b>	<b>Satomi Yoshida</b> , Kyoto University, Japan <b>Jung-Won Park</b> , Yonsei University, Republic of Korea	<b>Richard Hill</b> , Therapeutic Goods Administration, Australia <b>Andrew Bate</b> , Pfizer, UK	<b>Robert W. Platt</b> , McGill University, Canada

14:00-14:15	<b>Anti-osteoporosis treatment pattern after hip or vertebral fractures among postmenopausal women in China - #218</b> Hongxin Zhao, Shanghai Synyi Medical Technology Co., Ltd, China	<b>Introduction</b> Richard Hill, Therapeutic Goods Administration, Australia	<b>Teaching the fundamentals of pharmacoepidemiology in a 'Big Data' world</b> Kristian Filion, McGill University, Canada
14:15-14:30	<b>Changes of National Health Insurance reimbursement criteria on drug prescribing patterns and medical expenditures of osteoporotic fractures - #219</b> Chen-Yu Wang, National Taiwan University, Taiwan	<b>Signal detection in distributed health data networks in the US: Lessons, barriers, and opportunities</b> Jeffrey Brown, Harvard Medical School and Harvard Pilgrim Health Care Institute, USA	<b>The use of platforms for teaching pharmacoepidemiology</b> Seoyoung C. Kim, Harvard Medical School, USA
14:30-14:45	<b>Osteoporotic fractures associated with the use of rivaroxaban vs warfarin or dabigatran among patients with atrial fibrillation - #220</b> Wallis Lau, UCL School of Pharmacy, UK; The University of Hong Kong, Hong Kong	<b>Signal detection for drug safety using Japanese Real World Data</b> Chieko Ishiguro, Pharmaceuticals and Medical Devices Agency (PMDA), Japan	<b>What pharmacoepidemiologists need to learn about machine learning</b> Nicole Pratt, University of South Australia, Australia
14:45-15:00	<b>A database study of clinical features and treatment patterns with biologics in patients with Crohn's disease in Japan - #221</b> Yanfang Liu, Janssen Research & Development, Singapore	<b>Multiple data stream surveillance for Real World Evidence generation</b> Andrew Bate, Pfizer, UK	<b>The use of distributed research network for teaching pharmacoepidemiology</b> Rae Woong Park, Ajou University, South Korea
15:00-15:15	<b>Prevalence, safety and long-term retention rates of biologics in Hong Kong from 2001 to 2015 - #222</b> Mengqin Ge, Li Ka Shing Faculty of Medicine, Hong Kong		<b>Discussion</b>
15:15-15:30	<b>Safety regarding infectious events of biosimilars compared to other drugs in rheumatoid arthritis: A systematic review and network meta-analyses - #223</b> Yao Chen, Peking University, China		
<b>15:30-16:15</b>	<b>Afternoon coffee break</b>		
<b>Room:</b>	Plenary Hall B		



## Sunday 13 October 2019 continued

16:15-17:45	<b>Contributed papers 11 - Cancer</b>	<b>Symposium 12 - Challenges and approaches to Pharmacoepidemiologic research in mental health</b>	<b>Symposium 13 - A new international collaboration to advance medication safety in people with neurodegenerative diseases: NeuroGEN</b>
Room:	Conference Room	Plenary Hall A	Exhibition Hall A
Chair/ Moderator:	Azusa Hara, Keio University, Japan Yea-Huei Kao Yang FISPE, National Cheng Kung University, Taiwan	Soko Setoguchi FISPE, Rutgers University, USA	Ian Wong, The University of Hong Kong, Hong Kong Simon Bell, Monash University, Australia
16:15-16:30	Estimation of healthcare costs for multiple myeloma in Japan using a nationwide claims database - #224 Jia Guan, Kyoto University, Japan	<b>Introduction</b> Tobias Gerhard FISPE, Public Health Rutgers University, USA	<b>Global collaboration to advance medication safety: Challenges, opportunities and where to from now?</b> Ian Wong, The University of Hong Kong, Hong Kong Simon Bell, Monash University, Australia
16:30-16:45	Use of Phosphodiesterase 5 inhibitors reduces risk of colorectal cancer in men with benign colorectal neoplasms - #225 Jianguang Ji, Lund University, Sweden	<b>Mortality risk of antipsychotic augmentation for depression</b> Tobias Gerhard FISPE, Public Health Rutgers University, USA	
16:45-17:00	Compare effectiveness of abiraterone and enzalutamide in patients with metastatic castration-resistant prostate cancer in Taiwan - #226 Yan-Lin Wang and Kai-Cheng Chang, Linkou Chang Gung Memorial Hospital, Taiwan	<b>Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD)</b> Ju-Young Shin, Sungkyunkwan University, South Korea	<b>Case study from the UK: Transforming a single country study into an international study</b> Wallis Lau, University College London, UK
17:00-17:15	Comparative efficacy and safety of angiogenesis inhibitors in the treatment of non-small cell lung cancer: Systematic review and network meta-analysis - #227 Kirati Kengkla and Surasak Saokaew, University of Phayao, Thailand	<b>Comparative mortality associated with ziprasidone and olanzapine (ZODIAC)</b> Brian Strom FISPE, Rutgers University, USA	<b>Case study from Australia: Investigating medication use and safety using only medication data</b> Jenni Iilomaki, Monash University, Australia
17:15-17:30	Comparing effectiveness of first-line tyrosine kinase inhibitors in advanced lung adenocarcinoma patients with EGFR mutation using real-world data - #228 Yi-Hsin Yang, National Institute of Cancer Research, Taiwan	<b>Questions and discussion</b> moderated by Soko Setoguchi FISPE, Rutgers University, USA	<b>Development of distributed network structures for NeuroGEN studies</b> Edward Lai, National Cheng Kung University, Taiwan
17:30-17:45	Treatment evolution and improved survival in multiple myeloma in Taiwan - #229 Yanfang Liu, Janssen Research & Development, Singapore		
<b>17:45-18:00</b>	<b>Closing, farewell and award ceremony</b>		
Room:	Plenary Hall A		
Chair:	Shiro Tanaka, Local Host Committee, Kyoto University, Japan Frank May FISPE, ACPE12 Conference Co-Chair James Vrac, Executive Secretary, International Society for Pharmacoepidemiology: <b>Presentation of 'Rising Star' Award:</b> Ms Samanta Lalic, Centre for Medicine Use and Safety, Monash University, Parkville, Australia, and Pharmacy Department, Austin Health, Melbourne, Australia 'Transition to high-dose or strong opioids: A population-based study of people initiating opioids in Australia' - #103 <b>Announcement of the Seoul ACPE13 meeting - 15-17 October 2020</b> Jung-Won Park and Nam-Kyong Choi		
18:00	End of day 2		